blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4052703

EP4052703 - METHOD FOR SUPPRESSING PRODUCTION OF ASENAPINE-N-OXIDE [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  05.08.2022
Database last updated on 27.07.2024
FormerThe international publication has been made
Status updated on  08.05.2021
Most recent event   Tooltip03.05.2024Amendment by applicant 
Applicant(s)For all designated states
Hisamitsu Pharmaceutical Co., Inc.
408, Tashirodaikan-machi
Tosu-shi, Saga 841-0017 / JP
[2022/36]
Inventor(s)01 / TAKAGI Yuka
c/o HISAMITSU PHARMACEUTICAL CO., INC., 1-25-11
Kannondai
Tsukuba-shi, Ibaraki 305-0856 / JP
02 / YUKUHIRO Masaki
c/o HISAMITSU PHARMACEUTICAL CO., INC., 1-25-11
Kannondai
Tsukuba-shi, Ibaraki 305-0856 / JP
 [2022/36]
Representative(s)Grünecker Patent- und Rechtsanwälte PartG mbB
Leopoldstraße 4
80802 München / DE
[2022/36]
Application number, filing date20881624.919.10.2020
[2022/36]
WO2020JP39240
Priority number, dateJP2019019512528.10.2019         Original published format: JP 2019195125
JP2020006370231.03.2020         Original published format: JP 2020063702
[2022/36]
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2021085211
Date:06.05.2021
Language:JA
[2021/18]
Type: A1 Application with search report 
No.:EP4052703
Date:07.09.2022
Language:EN
[2022/36]
Search report(s)International search report - published on:JP06.05.2021
(Supplementary) European search report - dispatched on:EP17.11.2023
ClassificationIPC:A61K31/407, A61K9/70, A61K47/02, A61P25/00, A61P25/18
[2023/51]
CPC:
A61P25/00 (EP,KR); A61K9/7038 (KR); A61K31/407 (EP,KR,US);
A61K47/02 (EP,KR,US); A61K47/20 (KR); A61K9/7053 (EP,US);
A61K9/7061 (EP); A61K9/7069 (EP); A61P25/18 (EP,KR) (-)
Former IPC [2022/36]A61K31/407, A61K9/70, A61K47/04, A61K47/20, A61K47/32, A61P25/00, A61P25/18
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/36]
TitleGerman:VERFAHREN ZUM UNTERDRÜCKEN DER PRODUKTION VON ASENAPIN-N-OXID[2022/36]
English:METHOD FOR SUPPRESSING PRODUCTION OF ASENAPINE-N-OXIDE[2022/36]
French:PROCÉDÉ DE SUPPRESSION DE LA PRODUCTION D'ASÉNAPINE-N-OXYDE[2022/36]
Entry into regional phase24.05.2022Translation filed 
24.05.2022National basic fee paid 
24.05.2022Search fee paid 
24.05.2022Designation fee(s) paid 
24.05.2022Examination fee paid 
Examination procedure24.05.2022Examination requested  [2022/36]
02.05.2024Amendment by applicant (claims and/or description)
02.05.2024Date on which the examining division has become responsible
Fees paidRenewal fee
24.05.2022Renewal fee patent year 03
27.10.2023Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[X]WO2018115010  (LTS LOHMANN THERAPIE SYSTEME AG [DE]) [X] 1-3 * paragraph [0168]; example -; claim 1 *;
 [XP]WO2019243432  (LTS LOHMANN THERAPIE SYSTEME AG [DE]) [XP] 1-3 * examples 2a, 2b, 3a-3e, 4a, 4b * * ref. examples 7b-7d * * paragraphs [0183] , [ 267] , [ 325] * * tables 2.2-2.7, 7.2, 7.3 *;
 [E]EP3861999  (HISAMITSU PHARMACEUTICAL CO [JP]) [E] 1-3* patch 13 *
International search[Y]WO2014207664  (ALEMBIC PHARMACEUTICALS LTD [IN]) [Y] 1-3* examples, claims *;
 [Y]WO2016140087  (HISAMITSU PHARMACEUTICAL CO [JP]) [Y] 1-3 * paragraph [0051] *;
 [Y]WO2017018322  (HISAMITSU PHARMACEUTICAL CO [JP]) [Y] 1-3 * paragraph [0032] *;
 [Y]WO2017018321  (HISAMITSU PHARMACEUTICAL CO [JP]) [Y] 1-3 * paragraph [0030] *;
 [Y]WO2018115001  (LTS LOHMANN THERAPIE SYSTEME AG [DE]) [Y] 1-3 * examples 9a, 9b, 10, 12a, 12b, 13a, 13b, claims 1, 64, paragraph [0207] *
by applicantWO2017018321
 WO2017018322
 WO2018115001
 WO2017018321
 WO2017018322
 WO2018115001
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.